Novartis to go forward with campaign

Article Abstract:

Swiss pharmaceutical company Novartis AG has launched its $10 million ad campaign developed by public relations firm Ruder-Finn. The campaign, postponed after the terrorist attacks on the US, does not name specific products but promotes a message in celebration of life. Two weeks after the terrorist attacks, the company feels its message is needed now more than ever and it is appropriate to launch the campaign. An inserted message at the end of the advertisements honors the lives of those lost in the attacks.

Switzerland, Advertising, Campaign Launched, Public Relations Agencies, Positioning, Campaign Themes, Public Relations, Public relations services, Contracts, Novartis AG, Public relations firms, NVTSY, Ruder Finn Inc.

---

TV dethrones magazines in drug ads

Article Abstract:

The trend to pharmaceuticals being advertised on television, directly to large groups of consumers, and less in magazines, has jumped dramatically since the FDA loosened the rules. But consumers who were surveyed were about equal in terms of which medium reached them. In fact, the older the consumer gets the less he trusts the drug companies in general. But magazines are concerned because of the severe drop in ad spending.

Television, Print Media, Demographics, Consumer Attitudes, Media Pricing, Standards, Telecommunications systems, Advertising, Mass media, United States. Food and Drug Administration

---

Amgen wins rights to sell anemia drug

Article Abstract:

An arbitration panel in Chicago has ruled in favor of Amgen, Inc. over Johnson & Johnson for the sole rights to sell NESP. Novel erythropoeisis stimulating protein (NESP) is used to treat anemia and is the successor to EPO that both firms have sold for the last 10 years. NESP is still in clinical trials, but when it reaches the market in 2001, Amgen could have well over a one billion dollar a year product.

Comment:

Co. wins the sole right to sell NESP, an anemia drug

Product information, Company Planning/Goals, Legal/Government Regulation, Cases, Amgen Inc., AMGN

Similar abstracts:

• Abstracts: EarthLink starts free-thinker campaign. Juno Online jumps into supercomputing. Firm develops method to track AOL advertisers
• Abstracts: EarthLink starts free-thinker campaign. U.S. plans a campaign to boost morale
• Abstracts: CEOs give tax deal wary welcome. The right stuff. Coalition yes, Reith no
• Abstracts: Food exporters go online. Foster's takes a loss on Wine Planet. Buoyancy test
• Abstracts: Precision instrument industry. part 3

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.